Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Passes Above 200-Day Moving Average – What’s Next?

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) shares crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $4.11 and traded as high as $5.91. Cumberland Pharmaceuticals shares last traded at $5.57, with a volume of 50,301 shares trading hands.

Wall Street Analyst Weigh In

Several research analysts recently commented on CPIX shares. Wall Street Zen downgraded shares of Cumberland Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Cumberland Pharmaceuticals Stock Performance

The firm has a 50 day moving average of $4.86 and a 200-day moving average of $4.11. The company has a market cap of $83.44 million, a P/E ratio of -11.37 and a beta of 0.08. The company has a quick ratio of 0.79, a current ratio of 0.95 and a debt-to-equity ratio of 0.25.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last issued its earnings results on Tuesday, May 5th. The specialty pharmaceutical company reported ($0.13) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.13). The business had revenue of $9.13 million during the quarter, compared to analyst estimates of $8.50 million. Cumberland Pharmaceuticals had a negative return on equity of 12.01% and a negative net margin of 17.60%.

Hedge Funds Weigh In On Cumberland Pharmaceuticals

Several institutional investors have recently made changes to their positions in CPIX. XTX Topco Ltd bought a new stake in shares of Cumberland Pharmaceuticals in the second quarter valued at about $34,000. Arrowstreet Capital Limited Partnership purchased a new stake in Cumberland Pharmaceuticals in the first quarter worth about $66,000. Two Sigma Investments LP grew its holdings in Cumberland Pharmaceuticals by 16.5% during the 3rd quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock worth $117,000 after acquiring an additional 5,326 shares in the last quarter. Marshall Wace LLP purchased a new position in Cumberland Pharmaceuticals during the 4th quarter valued at about $192,000. Finally, Geode Capital Management LLC increased its position in Cumberland Pharmaceuticals by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company’s stock valued at $427,000 after purchasing an additional 5,653 shares during the period. Hedge funds and other institutional investors own 15.51% of the company’s stock.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.